MET expression

These findings demonstrate that H. pylori can infect the 3D liver model and induce apoptosis and signaling alterations in hepatocytes, suggesting a potential pathological impact on the liver. Further studies are required to determine whether similar effects occur in the human liver in vivo.

On this basis, we developed IR788-Crizotinib, a c-Met-targeted near-infrared window-II (NIR-II) fluorescent probe, and evaluated its imaging performance in subcutaneous xenograft, 4-NQO-induced oral lesion, orthotopic tongue OSCC and lymph node metastasis mouse models...In cervical lymph nodes, it detected micro-metastatic foci as small as 342 μm, with 100% sensitivity. c-Met-targeted NIR-II imaging provides an integrated visualization strategy for premalignant lesion screening, primary tumor delineation and metastatic lymph node detection in OSCC, with translational potential for precision management of oral cancer.

Crizotinib showed no significant difference in progression-free survival (PFS) or overall survival (OS) between first-line and post-chemotherapy use (PFS: p = 0.803; OS: p = 0.761). For second-generation ALK-TKIs, first-line treatment had numerically longer PFS compared to post-chemotherapy (alectinib: 41 vs 24 months; ceritinib: 30 vs 8 months), but these differences were not statistically significant after adjustment (p = 0.120 and 0.284, respectively)...Among patients treated with alectinib, there appears to be a trend toward shorter PFS and OS in those with MET overexpression. In a limited number of matched samples, PD-L1 expression did not change significantly after TKI resistance, although a slight increase was observed.

These findings demonstrate that MET dysregulation is a recurrent molecular event in ampullary carcinoma and support further investigation of MET and HER2 co-expression as a basis for future mechanistic and therapeutic studies.

Also, smaller tumors had higher c-MET intensity scores (r = -0.579, P = 0.038). Most GCTs were c-MET positive by immunostaining along with the vascular endothelial cells, highlighting the potential of c-MET inhibition as a therapeutic option in these tumors.

Importantly, rutin exhibits synergistic effects with temozolomide (TMZ), significantly inhibiting tumor growth and prolonging survival in YANK2 overexpressing orthotopic glioma models. Collectively, these findings establish YANK2 as a novel prognostic biomarker and a promising therapeutic target, and highlight rutin as a potential chemosensitizer for biomarker driven combination therapy in glioma.

These results indicate c-Met protein overexpression can be assessed before or after treatment since most patients maintain consistent c-Met status. As targeted therapies may elevate c-Met overexpression over time, retesting may be necessary in those with an oncogenic driver alteration initially diagnosed as c-Met negative.

Moreover, comprehensive in vitro and in vivo experiments demonstrate that nitidine significantly inhibits tumor progression through an LRPPRC-MET-G4-dependent mechanism. Collectively, our study suggests an epigenetic regulatory mechanism involving LRPPRC-MET-G4-mediated MET upregulation and provides a promising therapeutic strategy for MET-driven tumors using molecular glues that target the LRPPRC-MET-G4 interface.

In this study, we demonstrated that HOXA9 drove the expression of the fusion gene EPHB4-MET and exerted a tumorigenesis signature. HOXA9 may be a useful target for both diagnosis and treatment in patients with EPHB4-MET fusion genes in lung cancer.

Following discontinuation of Savolitinib due to drug-induced liver injury, Tislelizumab, previously associated with resistance, was reintroduced as a "rechallenge" successfully re-establishing disease control. Coupled with a systematic review of pertinent literature, this article explores the clinical features, therapeutic challenges, potential resistance mechanisms, and management approaches for such patients. It also outlines future research avenues for combination or sequential therapies, aiming to furnish a more holistic reference for clinical decision-making.

P2, N=252, Not yet recruiting, Shanghai Allink Biotherapeutics Co., Ltd.

HP BMSC transplantation correlates with early molecular events in acute liver failure mice, including upregulation of VEGF, HGF, and c-Met expression and changes in CD24⁺CD38⁺ B lymphocyte subsets, providing correlative evidence for involvement of the VEGF/c-Met pathway.